Annovis Bio Receives NYSE Notice for Failing Continued Listing Standards

PUBT · 20h ago
Annovis Bio Receives NYSE Notice for Failing Continued Listing Standards
  • Annovis Bio received an NYSE noncompliance notice on October 29, 2026, for breaching market capitalization and stockholders' equity requirements of $50 million each.
  • Average 30-trading-day market capitalization was $48.4 million on October 28, 2026; stockholders' deficit was $4.3 million as of June 30, 2026.
  • The company plans to submit a compliance plan within 45 days of the notice, targeting compliance within nine months of receipt.
  • NYSE will initiate delisting proceedings if the plan is late or rejected; failure to regain compliance also risks suspension and delisting.
  • The notice has no immediate listing impact; common stock will carry a “.BC” designation until compliance is restored.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annovis Bio Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610301700PRIMZONEFULLFEED9857351) on October 30, 2026, and is solely responsible for the information contained therein.